India, Nov. 5 -- Dyne Therapeutics, Inc. (DYN), a clinical-stage biotechnology company focused on genetically driven neuromuscular diseases, reported a wider third-quarter 2026 net loss, primarily reflecting higher research and development expenses and preparations for potential product launches.
Net loss increased to $193.6 million, or $1.06 per share, from $108.0 million, or $0.76 per share, a year earlier.
R&D expenses rose to $161.7 million from $97.2 million, while general and administrative expenses increased to $35.3 million from $16.7 million.
The company ended September 30, 2026, with $1.134 billion in cash, cash equivalents and marketable securities, which it expects to fund operations into the second quarter of 2028.
googleta...